Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

12 janv. 2021 10h10 HE | Source: NX Development Corp.

NX Development Corp. (NXDC) Receives FDA Orphan-Drug Designation for Gleolan® (aminolevulinic acid HCl) in Meningioma

Lexington, KY, Jan. 12, 2021 (GLOBE NEWSWIRE) -- NX Development Corp. (NXDC), a life sciences company wholly owned by photonamic GmbH & Co. KG., today announced FDA orphan-drug designation for...
17 nov. 2020 14h12 HE | Source: NX Development Corp.

NX Development Corp. (NXDC) Launches Gleolan (aminolevulinic acid HCl) Meningioma Phase III Clinical Trial (NXDC-MEN-301)

Lexington, KY, Nov. 17, 2020 (GLOBE NEWSWIRE) -- NX Development Corp (NXDC), a life sciences company wholly owned by photonamic GmbH & Co. KG., today announced the enrollment of the first...
03 oct. 2019 12h58 HE | Source: NX Development Corp.

Lexington-Based NX Development Corp (NXDC) Announces Baptist Health Lexington is First Hospital in Kentucky to Use Breakthrough Imaging Agent for Brain Tumor Visualization

Lexington, KY, Oct. 03, 2019 (GLOBE NEWSWIRE) -- NX Development Corp (NXDC), a life sciences company based in Lexington, KY, today announced Baptist Health Lexington is the first hospital in state...